Advancement of Antigen-specific Immunotherapy: Knowledge Transfer Between Allergy and Autoimmunity

Overview

Journal Immunother Adv

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2022 Aug 3

PMID 35919740

Authors

Naomi Richardson

David Cameron Wraith

Affiliations

Soon will be listed here.

Abstract

Targeted restoration of immunological tolerance to self-antigens or innocuous environmental allergens represents the ultimate aim of treatment options in autoimmune and allergic disease. Antigen-specific immunotherapy (ASI) is the only intervention that has proven disease-modifying efficacy as evidenced by induction of long-term remission in a number of allergic conditions. Mounting evidence is now indicating that specific targeting of pathogenic T cells in autoinflammatory and autoimmune settings enables effective restoration of immune homeostasis between effector and regulatory cells and alters the immunological course of disease. Here, we discuss the key lessons learned during the development of antigen-specific immunotherapies and how these can be applied to inform future interventions. Armed with this knowledge and current high-throughput technology to track immune cell phenotype and function, it may no longer be a matter of 'if' but 'when' this ultimate aim of targeted tolerance restoration is realised.

Citing Articles

Soluble antigen arrays provide increased efficacy and safety over free peptides for tolerogenic immunotherapy.

Firdessa-Fite R, Johnson S, Bechi Genzano C, Leon M, Ku A, Ocampo Gonzalez F Front Immunol. 2024; 15:1258369.

PMID: 38933266 PMC: 11199391. DOI: 10.3389/fimmu.2024.1258369.

Tolerance-inducing therapies in coeliac disease - mechanisms, progress and future directions.

Sollid L Nat Rev Gastroenterol Hepatol. 2024; 21(5):335-347.

PMID: 38336920 DOI: 10.1038/s41575-024-00895-3.

Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications.

Kaps L, Limeres M, Schneider P, Svensson M, Zeyn Y, Fraude S Int J Mol Sci. 2023; 24(14).

PMID: 37511628 PMC: 10380755. DOI: 10.3390/ijms241411869.

Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant.

Martens P, Ellis D, Bruggeman Y, Viaene M, Laureys J, Teyton L Front Endocrinol (Lausanne). 2022; 13:1023264.

PMID: 36339431 PMC: 9630573. DOI: 10.3389/fendo.2022.1023264.

Immunotherapy advances: One year on.

Elliott T Immunother Adv. 2022; 2(1):ltac001.

PMID: 35919492 PMC: 9327108. DOI: 10.1093/immadv/ltac001.

References

Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C . Expanding antigen-specific regulatory networks to treat autoimmunity. Nature. 2016; 530(7591):434-40. DOI: 10.1038/nature16962. View

Jutel M, Agache I, Bonini S, Burks A, Calderon M, Canonica W . International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016; 137(2):358-68. DOI: 10.1016/j.jaci.2015.12.1300. View

Carambia A, Freund B, Schwinge D, Heine M, Laschtowitz A, Huber S . TGF-β-dependent induction of CD4⁺CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells. J Hepatol. 2014; 61(3):594-9. DOI: 10.1016/j.jhep.2014.04.027. View

Zimmer R, Scherbarth H, Rillo O, Gomez-Reino J, Muller S . Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2012; 72(11):1830-5. PMC: 3812851. DOI: 10.1136/annrheumdis-2012-202460. View

Larche M, Akdis C, Valenta R . Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006; 6(10):761-71. DOI: 10.1038/nri1934. View

Wasserman R, Hague A, Pence D, Sugerman R, Silvers S, Rolen J . Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. J Allergy Clin Immunol Pract. 2018; 7(2):418-426.e4. DOI: 10.1016/j.jaip.2018.05.023. View

Francis J, James L, Paraskevopoulos G, Wong C, Calderon M, Durham S . Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008; 121(5):1120-1125.e2. DOI: 10.1016/j.jaci.2008.01.072. View

Shepard E, Wegner A, Hill E, Burton B, Aerts S, Schurgers E . The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases. Front Immunol. 2021; 12:654201. PMC: 8079784. DOI: 10.3389/fimmu.2021.654201. View

Anderton S, Manickasingham S, Burkhart C, Luckcuck T, Holland S, Lamont A . Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J Immunol. 1998; 161(7):3357-64. View

10.

Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M . Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. J Allergy Clin Immunol. 2016; 138(1):162-8. DOI: 10.1016/j.jaci.2016.02.044. View

11.

Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M . Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018; 558(7710):454-459. PMC: 6130914. DOI: 10.1038/s41586-018-0206-z. View

12.

Ludvigsson J, Wahlberg J, Casas R . Intralymphatic Injection of Autoantigen in Type 1 Diabetes. N Engl J Med. 2017; 376(7):697-699. DOI: 10.1056/NEJMc1616343. View

13.

Miller A, Lider O, Weiner H . Antigen-driven bystander suppression after oral administration of antigens. J Exp Med. 1991; 174(4):791-8. PMC: 2118953. DOI: 10.1084/jem.174.4.791. View

14.

Pfaar O, Bachert C, Kuna P, Panzner P, Dzupinova M, Klimek L . Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. J Allergy Clin Immunol. 2018; 143(3):970-977. DOI: 10.1016/j.jaci.2018.11.018. View

15.

Klimek L, Bachert C, Lukat K, Pfaar O, Meyer H, Narkus A . Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy. 2015; 5:28. PMC: 4553934. DOI: 10.1186/s13601-015-0071-x. View

16.

Pellaton C, Perrin Y, Boudousquie C, Barbier N, Wassenberg J, Corradin G . Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy. 2013; 3(1):17. PMC: 3672070. DOI: 10.1186/2045-7022-3-17. View

17.

Gardner L, OHehir R, Rolland J . High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T Cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol. 2003; 133(1):1-13. DOI: 10.1159/000075248. View

18.

Perona-Wright G, Anderton S, Howie S, Gray D . IL-10 permits transient activation of dendritic cells to tolerize T cells and protect from central nervous system autoimmune disease. Int Immunol. 2007; 19(9):1123-34. DOI: 10.1093/intimm/dxm084. View

19.

Burkhart C, Liu G, Anderton S, Metzler B, Wraith D . Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol. 1999; 11(10):1625-34. DOI: 10.1093/intimm/11.10.1625. View

20.

Schulten V, Tripple V, Aasbjerg K, Backer V, Lund G, Wurtzen P . Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy. Clin Exp Allergy. 2015; 46(3):439-48. PMC: 4767546. DOI: 10.1111/cea.12653. View